• Cardiff Oncology filed a lawsuit on May 19, 2026 against Nerviano Medical Sciences in the US District Court for the Southern District of California over a dispute tied to its onvansertib license agreement.
• The complaint seeks an injunction to keep NMS performing under the agreement, plus a court declaration that Cardiff did not materially breach it.
• NMS issued a breach notice on Feb. 24, 2026, alleging Cardiff failed to name an NMS employee as a joint inventor on US Patent Nos. 12,144,813 and 12,263,173, plus failed to agree to file a joint invention continuation application.
• Cardiff disputes the claim, arguing the agreement does not require listing NMS employees on inventions made exclusively by Cardiff or making what it views as inaccurate inventorship filings with the US Patent and Trademark Office.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-231040), on May 19, 2026, and is solely responsible for the information contained therein.